06/30
Headlines

NASDAQ:LJPC

Best Stocks – La Jolla Pharmaceutical Company (NASDAQ:LJPC) , Nektar Therapeutics (NASDAQ:NKTR) , International Tower Hill Mines (NYSEMKT:THM) , Lions Gate Entertainment (NYSE:LGF)

John Bellich02 mins

In a research report released on Wednesday, Noble Financial lifted price target for La Jolla Pharmaceutical Company (NASDAQ:LJPC) stock from $34 per share to $38 per share. La Jolla Pharmaceutical Company (NASDAQ:LJPC) stock performance was 1.88% in last session and finished the day at $10.85. Traded volume was 271,034.00million shares in the last session and…

Read More

Trending Tickers – La Jolla Pharmaceutical Company (NASDAQ:LJPC) , Trex Company, Inc. (NYSE:TREX) , ResMed Inc. (NYSE:RMD), StemCells Inc (NASDAQ:STEM)

John Meady02 mins

La Jolla Pharmaceutical Company (NASDAQ:LJPC) filed an S-3 on June 27 for a stock-and-warrant offering of $150M.Wedbush raises its PT to $45 from $34, representing a ~4x rise from today’s price. This is a clear signal that it is an underwriter on the issue. La Jolla Pharmaceutical Company (NASDAQ:LJPC) stock performance was 18.99% in last…

Read More

Biotech gainers: Insmed Incorporated (NASDAQ:INSM), Prothena Corporation (NASDAQ:PRTA), La Jolla Pharmaceutical Company (NASDAQ:LJPC), Biota Pharmaceuticals (NASDAQ:BOTA)

John Bellich02 mins

Some days before, shares of Insmed Incorporated (NASDAQ:INSM) fell double digits after the company reported data on a 90 patient Phase 2 trial. Insmed Incorporated (NASDAQ:INSM) stock performance was 7.02% in last session and finished the day at $13.41. Traded volume was 1.55million shares in the last session and the average volume of the stock…

Read More
FB Nasdaq FB Facebook

Biotech Losers: Agenus Inc (NASDAQ:AGEN), La Jolla Pharmaceutical Company (NASDAQ:LJPC), Durata Therapeutics (NASDAQ:DRTX), Galmed Pharmaceuticals (NASDAQ:GLMD)

Kevin Long02 mins

Shares of Agenus Inc (NASDAQ:AGEN) , a biopharmaceutical company focused on developing novel immunotherapies to treat cancer and a number of other unmet diseases, tumbled by as much as 22% after partner GlaxoSmithKline (NYSE: GSK ) announced that its phase 3 MAGE-A3 cancer immunotherapeutic trial in non-small cell lung cancer (NSCLC) patients didn’t meet its…

Read More

Biotech Losers: Discovery Laboratories (NASDAQ:DSCO), CEL-SCI Corporation (NYSEMKT:CVM), NewLink Genetics (NASDAQ:NLNK), La Jolla Pharmaceutical (NASDAQ:LJPC)

Mark Doerr02 mins

Discovery Laboratories, Inc. (NASDAQ:DSCO) has been upgraded by TheStreet Ratings from sell to hold. Discovery Laboratories, Inc. (NASDAQ:DSCO) stock performance was -6.01% in last session and finished the day at $2.19. Traded volume was 1,245,476 million shares in the last session and the average volume of the stock remained 589.46 million shares. The beta of…

Read More

Biotech Unusual Volume Stocks: Arca Biopharma (NASDAQ:ABIO), Biota Pharmaceuticals (NASDAQ:BOTA), Lpath (NASDAQ:LPTN), La Jolla Pharmaceutical (NASDAQ:LJPC)

Mark DeFrance02 mins

Arca Biopharma Inc (NASDAQ:ABIO) focuses on developing genetically targeted therapies for cardiovascular disease. Its lead product candidate, Gencaro, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation in patients with heart failure and reduced left ventricular ejection fraction. Arca Biopharma Inc (NASDAQ:ABIO) stock performance was 11.34% in…

Read More